Bifunctional Compounds Degrade ITK via Ubiquitin Proteasome Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective mechanisms for targeting and degrading IL-2 inducible T-cell kinase (ITK), a key enzyme involved in inflammatory, autoimmune, and proliferative diseases, limiting treatment options for conditions such as allergic asthma, atopic dermatitis, and T-cell lymphomas.
Innovation Solution
Development of bifunctional compounds comprising an ITK hook, a ubiquitin ligase harness, and a linker that bind to ITK, facilitating its degradation through ubiquitination, thereby inhibiting its activity and providing a therapeutic approach for inflammatory, autoimmune, and proliferative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat ITK-mediated diseases, then treatment options are limited, but the lack of effective degradation mechanisms prevents adequate therapeutic effect
Solution Approach 1:
The bifunctional compound is divided into two distinct functional modules: an ITK-binding hook and a ubiquitin ligase harness, connected by a linker. This segmentation allows each module to independently perform its specific function (ITK binding and ubiquitin ligase recruitment) while working together to achieve proteolytic degradation, resolving the contradiction between reliable therapeutic effect and treatment versatility.
Solution Approach 2:
The bifunctional compound integrates multiple functions into a single molecule: ITK binding, ubiquitin ligase recruitment, and facilitation of proteolytic degradation. This multi-functionality provides a versatile therapeutic approach that can target ITK-mediated diseases through a novel mechanism, expanding treatment options while ensuring reliable therapeutic effect through direct degradation.
2Adaptability or versatility
If bifunctional compounds are developed to degrade ITK, then treatment options expand, but the molecular complexity increases
Solution Approach 1:
The linker serves as an intermediary component connecting the ITK-binding hook and the ubiquitin ligase harness. This mediator allows the two functional modules to be spatially separated yet functionally connected, enabling the compound to bridge ITK and ubiquitin ligase without requiring direct integration of complex structures, thus managing molecular complexity while expanding treatment options.
Solution Approach 2:
The invention extracts the essential functional elements (ITK-binding moiety and ubiquitin ligase-recruiting moiety) from complex biological systems and combines them into a simplified bifunctional compound. This extraction approach reduces molecular complexity by focusing only on the critical components needed for ITK degradation, while still providing versatile treatment options.
3Reliability
If ITK is targeted for degradation, then therapeutic efficacy improves, but the mechanism requires novel bifunctional compound design
Solution Approach 1:
The bifunctional compound employs a nested structure where the ubiquitin ligase harness is positioned to recruit E3 ligase, which then acts on the ITK-bound complex. This nesting of functional elements (hook binding ITK, harness recruiting ligase, ligase tagging ITK for degradation) achieves reliable therapeutic efficacy through coordinated action while managing design complexity through hierarchical organization.
Solution Approach 2:
The bifunctional compound is designed to preliminarily bind ITK through the hook portion before recruiting the ubiquitin ligase for degradation. This preliminary binding action ensures specific targeting of ITK before the degradation mechanism is activated, improving therapeutic efficacy while allowing for modular compound design that can be optimized independently for each functional step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade ITK in splenocytes and in vivo, offering a promising treatment mechanism for inflammatory, autoimmune, and proliferative diseases by targeting ITK for proteolytic degradation, potentially addressing the limitations of existing therapies.
Implementation Method 1
The compounds of Formula (A) are capable of targeting ITK for degradation under the appropriate conditions, for instance in a cell. As shown in the Examples herein, the compounds of Formula (A) degrade ITK in splenocytes and in vivo.
Implementation Method 2
The compounds effectively degrade ITK in splenocytes and in vivo, offering a promising treatment mechanism for inflammatory, autoimmune, and proliferative diseases by targeting ITK for proteolytic degradation
Data Source
AI summary
This disclosure relates to compounds of formulae I, II and III useful for degrading ITK via a ubiquitin proteolytic pathway. This disclosure also provides pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various diseases, conditions, and/or disorders.